[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

The World Market for Diabetes Treatments

October 2010 | 260 pages | ID: T8A4DCFF964EN
Kalorama Information

US$ 2,995.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Price (Single User PDF): $2,995.00
Price (Global Site License): $5,990.00


This Kalorama Information report , The World Market for Diabetes Treatments, provides market estimates and forecasts for the world market for diabetes treatments. The diabetes market is one of the fastest growing markets within the pharmaceutical sector, and is one of the few pharmaceutical sectors that are likely to continue to grow at double digit rates throughout the forecast period. Major contributing factors to growth are increasing obesity and an aging worldwide population. The total market for diabetes treatments is divided into two major segments:
  • Insulin Markets in US, Europe, Japan, ROW
  • Oral Hypoglycemics in US, Europe, Japan, ROW
For each of these market segments the report provides market share and regional breakout (US, Europe, Asia, ROW). The report also discusses treatment for diabetes complications and natural and herbal treatments.

The report’s geographic scope is worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market. Trends covered in the report include:
  • New Products and the Development Pipeline (Afrezza, Bydureon, Syncria, AVE0010, Balaglitazone, Metgluna Otelixizumab and others)
  • Transplantation Research Efforts
  • Β-Cell Transplantation Research
  • Potential New Drug for Type 2 Diabetes
  • Insulin Pills
  • Three-month Insulin Shot
  • Outsourcing of Diabetes Projects
  • Reclassification of Cause of Death
Information is presented as a worldwide overview, with special emphasis on the U.S., Europe, and other key markets. A market summary includes market analysis by product and region and a competitive analysis of leading providers. Additionally, key company profiles are included, including profiles of the following:
  • Amylin Pharmaceuticals
  • AstraZeneca
  • GlaxoSmithKline
  • Eli Lilly & Co.
  • Merck
  • Metabolex, Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi-Aventis Group
  • Takeda Pharmaceutical Company Limited
CHAPTER ONE: EXECUTIVE SUMMARY

Background
Scope and Methodology
Size and Growth of the Market
Key Issues and Trends Affecting Market
Leading Competitors

CHAPTER TWO: INTRODUCTION

Background
Therapeutic Practices
France
Germany
Italy
Japan
Spain
United Kingdom
United States
China
India

CHAPTER THREE: CURRENT THERAPEUTICS FOR DIABETES

Insulin
Regular Insulin
Long-Acting and Basal Insulin
Rapidly Acting Insulin
Combinations
Insulin Pumps
Insulin Pens
Inhaled Insulin
Other Treatments
Oral Hypoglycemics
Sulfonylureas Biguanides
a-Glucosidase Inhibitors
Thiazolidinediones
Meglitinides
D-Phenylalanine Derivatives
GLP1 Agonists
DPP-IV Inhibitor
Current Therapeutics for Diabetic Complications
Antihypertensive Therapy
ACE Inhibitors
a/a(Alpha/Beta)-Blockers
Calcium Channel Blockers
Diuretics
Angiotensin II Receptor Antagonists
Dyslipidemia Therapy
HMG-CoA Reductase Inhibitors--Statins
Bile Acid Sequestrants
Fibric Acid Derivatives
Niacin
Cholesterol Absorption Inhibitors
Atherosclerosis Therapy
Arrhythmia Therapy
Peripheral Vascular Disease Therapy

CHAPTER THREE: TOTAL MARKET REVENUES, FORECAST AND COMPETITIVE ANALYSIS

Total Worldwide Diabetes Market Analysis by Geographic Segment
Total Worldwide Diabetes Market Competitive Analysis
Total Worldwide Diabetes Market by Segment
Insulin
Oral Hypoglycemics

CHAPTER FOUR: KEY ISSUES, TRENDS AND DEVELOPMENTS

New Products and the Development Pipeline
Afrezza
Bydureon
Syncria
AVE0010 Once Daily and Twice Daily
Balaglitazone
Dapagliflozin and Dapagliflozin/Meformin Fixed Dose Combination
Degludec and Degludec Plus
Daimyd Vaccine
Dutogliptin
Glinsuma, Glufast, Metgluna
MK 0431C
Ondero
Oral-lyn
Otelixizumab
Taspoglutide
Transplantation Research Efforts
A-Cell Transplantation Research
Potential New Drug for Type 2 Diabetes
Insulin Pills
Three-month Insulin Shot
Outsourcing of Diabetes Projects
Reclassification of Cause of Death

CHAPTER FIVE: NUTRITIONAL SUPPLEMENT AND HERBAL APPROACHES TO THE TREATMENT OF DIABETES

Background
Nutritional Supplements
Ascorbic Acid (Vitamin C)
Biotin
Chromium
Copper
Magnesium
Niacin and Niacinamide
Potassium
Selenium
Thiamine
Vanadium
Vitamin B6 (Pyridoxine)
Vitamin B12
Vitamin E
Zinc
Nutritional Treatment of Diabetic Neuropathy
Herbal Treatment of Diabetes
Aloe (Various)
Arctium lappa (Burdock Root)
Allium cepa (Onion)
Grifola frondosa (Maitake Mushroom)
Mulberry
Panax ginseng (Korean ginseng)
Ayurvedic Medicine and Herbs
Gymnema sylvestre (Asclepias germinata)
Momordica charantia (Bitter Gourd)
Trigonella foenum graecum (Fenugreek)
Other Herbs with Significant Anti-Diabetic Effects
Traditional Chinese Medicine

CHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS


First Conclusion
Implications:
Second Conclusion
Implications:
Third Conclusion
Implications:
Fourth Conclusion
Implications:
Fifth Conclusion
Implications:
Sixth Conclusion
Implications:
Seventh Conclusion
Implications:
Eighth Conclusion
Implications:
Ninth Conclusion
Implications:
Tenth Conclusion
Implications:
Eleventh Conclusion
Implications:
Twelfth Conclusion
Implications:
Thirteenth Conclusion
Implications:
Fourteenth Conclusion
Implications:
Fifteenth Conclusion
Implications:

CHAPTER SEVEN: LEADING MANUFACTURERS


Overview
Amylin Pharmaceuticals
AstraZeneca
GlaxoSmithKline
Eli Lilly & Co.
Merck
Metabolex, Inc.
Novo Nordisk A/S
Pfizer Inc.
Sanofi-Aventis Group
Takeda Pharmaceutical Company Limited

APPENDIX A: GLOSSARY

APPENDIX B: COMPANY DIRECTORY



More Publications